Role of B-type natriuretic peptide (BNP) and NT-PROBNP in clinical routine

Heart

Volumn 92, Issue 6, 2006, Pages 843-849

  Weber, Michael ^a   Hamm, Christian ^a  

^a KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARDIOTOXIN; CARVEDILOL; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HORMONE PRECURSOR; INTERLEUKIN 6; NATRIURETIC PEPTIDE TYPE C; PLACEBO; TIROFIBAN; TROPONIN; URODILATIN;

ACUTE CORONARY SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVERSION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DECISION MAKING; DRUG INHIBITION; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VALVULAR HEART DISEASE;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; EMERGENCY TREATMENT; HEART FAILURE, CONGESTIVE; HEART VALVE DISEASES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 33744457002     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.071233     Document Type: Review

References (24)

1. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22. This review summarises present knowledge on the physiology of BNP and provides comprehensive data on the diagnostic and therapeutic potential of BNP in patients with heart failure.
2. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
3. Luchner A, Hengstenberg C, Lowel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005;46:118-23.
4. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7. The Breath Not Properly (BNP) study provided important data on the diagnostic performance of BNP to detect heart failure in patients presenting to the emergency department with the cardinal symptom of shortness of breath.
5. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.
6. Wieczorek SJ, Wu AH, Christenson R, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002;144:834-9.
7. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54. The BASEL study demonstrated that BNP measurement in the emergency department reduces hospitalisation rate and total treatment costs with comparable clinical outcome.
8. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation 2003;107:1278-83. To our knowledge this articles provides the largest database including BNP measurement and follow-up data of 4305 patients with heart failure.
9. Mueller T, Gegenhuber A, Poelz W, et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-12.
10. Knebel F, Schimke I, Pliet K, et al. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005;11(5 suppl):S38-41.
11. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted far decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
12. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30. This small study demonstrated for the first time that NT-proBNP guided treatment results in better clinical outcome compared to clinically guided therapy without NT-proBNP assessment.
13. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand heart failure group. J Am Coll Cardiol 2001;37:1781-7. This study showed that NT-proBNP is able to discern heart failure patients who derive a benefit from carvedilol treatment. Thus this study demonstrates that therapeutic implications can be derived from BNP and NT-proBNP assessment.
14. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the carvedilol prospective randomized cumulative survival (COPERNICUS) trial. Circulation 2004;1110:1780-6.
15. Jemberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cordial 2002;40:437-45.
16. Heeschen C, Hamm CW, Mitrovic V, et al. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004;110:3206-12. Among the large multicentre studies, the data from the PRISM trial emphasises the importance of serial NT-proBNP measurement for assessing dynamic risk stratification.
17. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
18. Jemberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 2003;42:1909-16.
19. Weber M, Dill T, Arnold R, et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004;148:612-20.
20. Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation 2003;108:2987-92.
21. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75. This study examines the prognostic information which can be derived from measurement of NT-proBNP in patients with stable coronary artery disease.
22. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 2003;107:1884-90.
23. Weber M, Arnold R, Rau M, et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005;26:1023-30.
24. Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109:2302-8. The presented data demonstrate that elevated BNP values in patients with aortic stenosis provide prognostic information for an unfavourable clinical course.